| PD-1/PD-L1免疫检查点抑制剂致心脏毒性的研究进展 |
| |
| 引用本文： | 余琳,李广平,周长钰,富华颖.PD-1/PD-L1免疫检查点抑制剂致心脏毒性的研究进展[J].肿瘤防治研究,2021,48(8):794-798. |
| |
| 作者姓名： | 余琳 李广平 周长钰 富华颖 |
| |
| 作者单位： | 300211 天津，天津市心血管病离子与分子机能重点实验室，天津医科大学第二医院心脏科，天津心脏病学研究所 |
| |
| 基金项目： | 天津市自然科学基金（16JCYBJC25000）；天津医科大学第二医院重点实验室科研基金（2018ZDSYS03）；天津医科大学第二医院临床研究课题（2019LC03） |
| |
| 摘 要： | 心脏毒性是抗肿瘤药物的严重不良反应，随着抗肿瘤药物的不断发展，免疫检查点抑制剂已被应用于多种癌症的治疗，特别是程序性死亡受体1（PD-1）或程序性死亡配体1（PD-L1）免疫检查点抑制剂近年来受到广泛关注，本文将从PD-1及PD-1/PD-L1免疫检查点抑制剂概述、PD-1/PD-L1免疫检查点抑制剂致心脏毒性的表现及可能机制的探索、心脏毒性的检测方法和PD-1/PD-L1所致心脏毒性的治疗等方面进行综述。
|
| 关 键 词： | PD-1/PD-L1 免疫检查点抑制剂 心脏毒性 进展 |
| 收稿时间： | 2020-12-11 |
Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors |
| |
| YU Lin,LI Guangping,ZHOU Changyu,FU Huaying.Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors[J].Cancer Research on Prevention and Treatment,2021,48(8):794-798. |
| |
| Authors: | YU Lin LI Guangping ZHOU Changyu FU Huaying |
| |
| Institution: | Department of Cardiology, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China |
| |
| Abstract: | Cardiotoxicity is a serious complication of antineoplastic drugs. With the continuous development of antineoplastic drugs, immune checkpoint inhibitors have been used in the treatment of a variety of cancers. PD-1/PD-L1 immune checkpoint inhibitors have been widely concerned in recent years. This article reviews the manifestations and possible mechanisms of cardiotoxicity induced by PD-1/PD-L1 immune checkpoint inhibitors, and the detection methods and treatment of cardiotoxicity. |
| |
| Keywords: | PD-1/PD-L1 Immune checkpoint inhibitors Cardiotoxicity Progress |
|
| 点击此处可从《肿瘤防治研究》浏览原始摘要信息 |
| 点击此处可从《肿瘤防治研究》下载免费的PDF全文 |
